Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 7Urinary Bladder Neoplasms 5Glioma 5Prostatic Neoplasms 4Lung Neoplasms 4Esophageal Neoplasms 4Burkitt Lymphoma 4Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Oropharyngeal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Astrocytoma 3Uterine Cervical Neoplasms 2Sarcoma, Ewing 2Sarcoma 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Mouth Neoplasms 2Mesothelioma, Malignant 2Melanoma 2Laryngeal Neoplasms 2Gliosarcoma 2Ganglioneuroblastoma 2Brain Neoplasms 2Adenocarcinoma of Lung 2Wilms Tumor 1Vulvar Neoplasms 1Vaginal Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

atezolizumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2talazoparib 1Radiotherapy 1Radiation 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Lung Small Cell Carcinoma × Radiation × 30 days × Clear all
NCT04402788 2026-06-02

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
138 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡